MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation

被引:49
作者
Tu, Hsi-Feng [2 ,3 ]
Chen, Hong-Wen [4 ]
Kao, Shou-Yen [2 ,3 ]
ina, Shu-Chun [2 ]
Liu, Chung-Ji [1 ,2 ,7 ]
Chang, Kuo-Wei [2 ,5 ,6 ]
机构
[1] Mackay Mem Hosp, Dept Oral & Maxillofacial Surg, Taipei 10449, Taiwan
[2] Natl Yang Ming Univ, Inst Oral Biol, Taipei 112, Taiwan
[3] Natl Yang Ming Univ Hosp, Dept Dent, Ilan, Taiwan
[4] Mackay Mem Hosp, Dept Radiat Oncol & Hosp Ctr, Taipei 10449, Taiwan
[5] Vet Gen Hosp, Dept Med Educ & Res, Taipei, Taiwan
[6] Vet Gen Hosp, Dept Dent & Res, Taipei, Taiwan
[7] Nursing & Management Coll, Taipei, Taiwan
关键词
carcinoma; MDM2; oral cavity; p53; polymorphism; radiotherapy;
D O I
10.1016/j.radonc.2008.03.018
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Purpose: The p53 tumor suppression pathway is important in effects associated with radiotherapy. The mouse double minute 2 (MDM2) plays a pivotal role in this pathway by down regulating p53. A functional T-to-G polymorphism at nucleotide 309 in MDM2 promoter intron 1 (SNP309) has been identified which influenced transcription activity. A G-to-C SNP at p53 codon 72 results in an Arg/Pro polymorphism, which is associated with apoptosis induction potential and p53 mutation status. Materials and methods: We sequenced both MDM2 SNP309 and p53 codon 72 SNP in patients with oral squamous cell carcinoma (OSCC, n = 189), oral submucosal fibrosis (OSF, n = 70), and 116 controls. Results: Neither MDM2 SNP309 nor p53 codon 72 SNP was associated with susceptibility to or the age at onset of OSCC or OSF. p53 codon 72 SNP Arg/Arg polymorphism was associated with the progression of OSCC, and the overall (OS) and disease-free survival (DFS) of irradiated patients. The MDM2 SNP309 G/G polymorphism was associated with poor OS in advanced OSCC, and the OS and DSF of irradiated patients. The combination of MDM2 SNP309 G/G and p53 codon 72 Arg/Arg polymorphism is associated with the worst OS and DFS. Conclusions: Advanced OSCC has high mortality and recurrence. We identified that both MDM2 SNP309 and p53 codon 72 SNP could be useful factors for evaluating the outcome of advanced OSCC treated with adjuvant radiation. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:243 / 252
页数:10
相关论文
共 49 条
[1]   Reasons to reconsider the significance of apoptosis for cancer therapy [J].
Abend, M .
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2003, 79 (12) :927-941
[2]   MDM2/p53 co-expression in oral premalignant and malignant lesions: potential prognostic implications [J].
Agarwal, S ;
Mathur, M ;
Srivastava, A ;
Ralhan, R .
ORAL ONCOLOGY, 1999, 35 (02) :209-216
[3]   The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck [J].
Alhopuro, P ;
Ylisaukko-oja, SK ;
Koskinen, WJ ;
Bono, P ;
Arola, J ;
Järvinen, HJ ;
Mecklin, JP ;
Atula, T ;
Kontio, R ;
Mäkitie, AA ;
Suominen, S ;
Leivo, I ;
Vahteristo, P ;
Aaltonen, LM ;
Aaltonen, LA .
JOURNAL OF MEDICAL GENETICS, 2005, 42 (09) :694-698
[4]   REGULATION OF MDM2 EXPRESSION BY P53 - ALTERNATIVE PROMOTERS PRODUCE TRANSCRIPTS WITH NONIDENTICAL TRANSLATION POTENTIAL [J].
BARAK, Y ;
GOTTLIEB, E ;
JUVENGERSHON, T ;
OREN, M .
GENES & DEVELOPMENT, 1994, 8 (15) :1739-1749
[5]   Significance of HDMX-S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis [J].
Bartel, F ;
Schulz, J ;
Böhnke, A ;
Blümke, K ;
Kappler, M ;
Bache, M ;
Schmidt, H ;
Würl, P ;
Taubert, H ;
Hauptmann, S .
INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (03) :469-475
[6]   p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis [J].
Bergamaschi, D ;
Gasco, M ;
Hiller, L ;
Sullivan, A ;
Syed, N ;
Trigiante, G ;
Yulug, I ;
Merlano, M ;
Numico, G ;
Comino, A ;
Attard, M ;
Reelfs, O ;
Gusterson, B ;
Bell, AK ;
Heath, V ;
Tavassoli, M ;
Farrell, PJ ;
Smith, P ;
Lu, X ;
Crook, T .
CANCER CELL, 2003, 3 (04) :387-402
[7]   A single nucleotide polymorphism in the MDM2 gene:: From a molecular and cellular explanation to clinical effect [J].
Bond, GL ;
Hu, WW ;
Levine, A .
CANCER RESEARCH, 2005, 65 (13) :5481-5484
[8]   A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans [J].
Bond, GL ;
Hu, WW ;
Bond, EE ;
Robins, H ;
Lutzker, SG ;
Arva, NC ;
Bargonetti, J ;
Bartel, F ;
Taubert, H ;
Wuerl, P ;
Onel, K ;
Yip, L ;
Hwang, SJ ;
Strong, LC ;
Lozano, G ;
Levine, AJ .
CELL, 2004, 119 (05) :591-602
[9]   MOLECULAR ANALYSIS AND CHROMOSOMAL MAPPING OF AMPLIFIED GENES ISOLATED FROM A TRANSFORMED MOUSE 3T3-CELL LINE [J].
CAHILLYSNYDER, L ;
YANGFENG, T ;
FRANCKE, U ;
GEORGE, DL .
SOMATIC CELL AND MOLECULAR GENETICS, 1987, 13 (03) :235-244
[10]   No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer [J].
Campbell, Ian G. ;
Eccles, Diana M. ;
Choong, David Y. H. .
CANCER LETTERS, 2006, 240 (02) :195-197